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Amphotericin B · Antimykotische Therapie, empirische · 
Itraconazol · Neutropenie · Fieber, ungeklärtes
Zusammenfassung
Hintergrund: Es wurden die Sicherheit, Verträglichkeit und Wirk-
samkeit von Itraconazol und Amphotericin B (AMB) in der antimy-
kotischen Therapie der persistierend febrilen Neutropenie ver-
glichen. Patienten und Methoden: In einer offenen, randomisierten
Studie erhielten 162 Patienten mit mindestens 72-stündiger antibio-
tischer Therapie entweder Itraconazol (erst intravenös, dann oral)
oder AMB (intravenös) für maximal 28 Tage. Primärer Sicherheits-
parameter war die dauerhafte Unterbrechung der Studienmedika-
tion aufgrund von Nebenwirkungen. Die Wirksamkeitsparameter
umfassten die Ansprech- und Erfolgsrate für beide Behandlungs-
gruppen. Ergebnisse: Signifikant weniger Itraconazol-Patienten bra-
chen die Behandlung wegen Nebenwirkungen ab (22,2 vs. 56,8%
AMB; p < 0,0001). Hauptursache für Studienabbrüche war der An-
stieg des Serum-Kreatinin-Spiegels (1,2% Itraconazol vs. 23,5%
AMB). Nephrotoxische und weitere Nebenwirkungen traten im
AMB-Studienarm signifikant häufiger auf. Intention-to-Treat (ITT)-
Analysen zeigten eine bessere Wirksamkeit von Itraconazol: An-
sprech- und Erfolgsrate waren signifikant höher als unter AMB (61,7
vs. 42% und 70,4 vs. 49,3%, beide p < 0,0001). Behandlungsversa-
gen trat bei Itraconazol-Patienten merklich weniger auf (25,9 vs.
43,2%). Schlussfolgerungen: Die Verträglichkeit von Itraconazol war
signifikant höher als beim herkömmlichen AMB. Itraconazol zeigte
ebenfalls Vorteile in der Wirksamkeit. Diese Studie bestätigt die
Rolle von Itraconazol als sinnvolles und sicheres Medikament in der
empirischen antimykotischen Therapie von fiebrigen neutropeni-
schen Tumorpatienten.
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Summary
Background: Safety, tolerability and efficacy of itraconazole and am-
photericin B (AMB) were compared for empirical antifungal treat-
ment of febrile neutropenic cancer patients. Patients and Methods:
In an open, randomised study, 162 patients with at least 72 h of
antimicrobial treatment received either intravenous followed by
oral itraconazole suspension or intravenous AMB for a maximum of
28 days. Permanent discontinuation of study medication due to any
adverse event was the primary safety parameter. Efficacy parame-
ters included response and success rate for both treatment groups.
Results: Significantly fewer itraconazole patients discontinued tre-
atment due to any adverse event (22.2 vs. 56.8% AMB; p < 0.0001).
The main reason for discontinuation was a rise in serum creatinine
(1.2% itraconazole vs. 23.5% AMB). Renal toxicity was significantly
higher and more drug-related adverse events occurred in the AMB
group. Intention-to-treat (ITT) analysis showed favourable effica-
cy for itraconazole: response and success rate were both signifi-
cantly higher than for AMB (61.7 vs. 42% and 70.4 vs. 49.3%, both
p < 0.0001). Treatment failure was markedly reduced in itracona-
zole patients (25.9 vs. 43.2%), largely due to the better tolerability.
Conclusions: Itraconazole was tolerated significantly better than
conventional AMB and also showed advantages regarding effica-
cy. This study confirms the role of itraconazole as a useful and
safe agent in empirical antifungal therapy of febrile neutropenic
cancer patients.
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Systemic fungal infections represent a major complication for
immunocompromised patients with malignant haematological
disorders and stem cell transplant (SCT) recipients. Prolonged
neutropenia is well recognised as a major risk factor for the
development of these infections [1]. The most frequent pre-
sentation is persistent fever unresponsive to broad-spectrum
antibiotics. The high mortality rates associated with estab-
lished infection call for empirical antifungal strategies in the
management of this high-risk patient group [2]. Several agents
with different safety and efficacy profiles are currently used
for empirical antifungal therapy. Conventional amphotericin
B (AMB) has a broad spectrum of antifungal activity but is as-
sociated with serious side effects, in particular nephrotoxicity.
New lipid formulations showed comparable efficacy to con-
ventional AMB in randomised controlled trials [3–5] and had
a better safety profile than the latter [6]. Second-generation
triazoles, (voriconazole and more recently posaconazole) have
emerged as suitable antifungal options [7, 8]. In recent years,
several clinical studies have investigated the safety and effica-
cy of another triazole, itraconazole (ITRA), both as oral and
intravenous formulation [9, 10]. ITRA proved efficacious both
in prophylaxis and treatment of systemic fungal infections in
patients with haematological malignancies and SCT recipients
(reviewed in e.g. Potter et al. [9]). Intravenous followed by
oral ITRA was at least as effective as empirical antifungal
therapy in neutropenic febrile cancer patients as AMB and
led to significantly fewer drug-related adverse events [10]. In
this study, we compared ITRA and AMB in a similar high-




This open, randomised, multicentre, parallel-group comparison was con-
ducted at 27 oncology centres in Germany between December 1999 and
August 2001. At enrolment, patients were stratified according to allo-
geneic SCT recipients (stratum 1), subjects with fever of unknown origin
(FUO) and lung infiltrates (stratum 2) and FUO patients without lung in-
filtrates (stratum 3). Central randomisation was performed in blocks of 4.
Patients were randomly assigned in a 1:1 ratio to receive either ITRA or
AMB. At each centre, balancing ensured that each treatment group was
allocated an equal number of subjects.
Independent ethics committees at all the participating institutions ap-
proved the study, and all patients provided written informed consent. The
study was conducted according to the Declaration of Helsinki, the Inter-
national Conference on Harmonization, and the Guidelines for Good
Clinical Practice.
Patients
Hospitalised subjects (≥ 18 years of age) with a haematological malig-
nancy treated by myelosuppressive therapy and/or who were allogene-
ic/autologous bone marrow or blood stem cell transplant recipients were
eligible for the study. Other inclusion criteria were a neutrophil count of
< 1.0 × 109 cells/l expected to last for at least 7 days from the start of the
study medication; fever ≥ 38 °C not responding to at least 72 h of broad-
spectrum antibiotics – potentially attributable to deep fungal infection –
and a life expectancy of at least 14 days. Patients with positive chest X-ray
findings (stratum 2) could be randomized as early as the first day of fever,
reflecting the higher incidence of fungal infections developing later in the
course of this risk category. Patients were excluded if they had previously
been entered into this study, participated in an investigational drug trial a
week prior to inclusion, or received investigational medication at enrol-
ment. Further exclusion criteria were serum creatinine > 2 times the
upper normal limit; serum glutamic pyruvic transaminase (SGPT) or
serum glutamic-oxaloacetic transaminase (SGOT) ≥ 5 times the upper
normal limit; bilirubin ≥ 5 mg/dl; human immunodeficiency virus (HIV)-
positive individuals; aplastic anaemia; known hypersensitivity to azole an-
tifungal agents or AMB; and treatment with terfenadine, astemizole, oral
midazolam, triazolam, cisapride, HMG-CoA reductase inhibitors, HIV
protease inhibitors, quinidine, pimozide, clarithromycin, carbamazepine,
isoniazide, phenytoin, rifabutin or rifampicin. Proven deep fungal infec-
tion at study entry or during previous episodes of neutropenia, proven
systemic bacterial or viral infection at study entry or superficial systemic
bacterial or viral infection responsible for the fever, continued treatment
with any systemic antifungal therapy (topical agents were allowed) and
treatment with AMB within 7 days prior to study entry also led to exclu-
sion. Pregnant or lactating females as well as females without a safe con-
traception method were not allowed to participate.
Study Medication
Patients received either ITRA or AMB until signs and symptoms were
cleared. The maximum treatment period was 28 days. Intravenous ITRA
was administered as a 40% hydroxypropyl-ß-cyclodextrin solution in
water at a loading dose of 200 mg every 12 h in a 1h-infusion for 2 days
followed by 200 mg every 24 h for 12 days. Patients then received an oral
solution of ITRA (200 mg) twice daily. However, if patients were able to
tolerate oral medication, oral ITRA could replace the intravenous admin-
istration earlier.
The recommended dose of AMB was 0.7–1 mg/kg/day. If the subject pre-
sented with an X-ray or computed tomography (CT) scan suggestive of
fungal infection, the dose could be adjusted to a maximum of 1.5 mg/kg/
day. Intravenous administration was preceded by infusion of 500–1,000 ml
of 0.9% sodium chloride (NaCl). Treatment could be interrupted if am-
photericin toxicity was suspected. In the case of discontinuation of study
medication due to poor tolerance, adverse events or deterioration of signs
and symptoms, patients could be switched from AMB to ITRA or vice
versa for a maximum treatment period of 28 days. This ‘follow-up’ treat-
ment was analysed separately.
Assessment of Safety and Efficacy
A complete clinical evaluation of the patient’s diagnosis, condition and
relevant medical and surgical history was carried out at enrolment. Fun-
gal, bacterial and viral surveillance cultures from blood, urine and other
suspected sites were taken at study entry and then once weekly. Isolated
organisms were identified down to species level. A chest X-ray or CT scan
was carried out at study entry and thereafter once weekly; bronchoscopy
was conducted if indicated. Body temperature was recorded daily (only
highest temperature per day); white blood cell count and neutrophil count
every second day. Haematological and biochemical laboratory parame-
ters were determined on days 0, 3, 8, 15, 22 and 28; creatinine clearance
was calculated from weight, age and serum creatinine levels on days 0, 3,
8, 11, 15, 18, 22, 25 and 28. Renal toxicity was defined as a doubling or in-
crease of 88 µmol/l in serum creatinine levels from baseline, or a decrease
of at least 50% in the calculated creatinine clearance from baseline. All
symptoms relating to fungal infection were documented twice per week.
All major clinical events during the study period were recorded. If cy-
closporin or tacrolimus were administered, plasma levels of both drugs
were determined twice weekly. Adverse events and concomitant therapy
were monitored daily. Type (defined by WHO ART dictionary) and inci-
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dence of all adverse events, intensity and relation to study medication
were recorded. Assessment was continued as described above during the
cross-over period.
The primary objective of the study was to monitor the safety and tolera-
bility of the study medication with the proportion of subjects permanently
discontinuing treatment due to any adverse event as the primary parame-
ter. All randomised patients with at least 1 administered dose of study
medication were included in this analysis. A global evaluation was carried
out by the local investigators in cases of premature discontinuation, at the
end of study and after the cross-over period using the criteria ‘failure’,
‘unevaluable’ and ‘response’. For definitions see table 1.
Secondary objective was the efficacy of the study medication. Efficacy pa-
rameters at the end of study were the response rate defined as response /
(response + failure + unevaluable), the success rate defined as response /
(response + failure), the number of deep fungal infections, the time to re-
sponse, the time until defervescence, the number of febrile (> 38 °C) days
during treatment and the duration of hospitalisation. The study was de-
signed before the EORTC/MSG criteria for the diagnosis of fungal infec-
tions were published [11]. The protocol allowed ‘patients with CT scan
highly suggestive of deep fungal infection [...] and with progressive infil-
trates’ to be categorized as deep fungal infections even in the absence of
microbiological evidence. Baseline infections were those present on or be-
fore day 2 of the study, and breakthrough infections those with an onset
on day 3 or later. Fungal infections were reviewed by a blinded investiga-
tor [A.G.] on the basis of case report form (CRF) data. Parameters were
analysed using the intention-to-treat (ITT) population who had at least 1
drug administration and post-baseline efficacy data.
A composite endpoint analysis according to Walsh et al. [5] was per-
formed with slight modifications: overall treatment response was defined
as survival for 7 days after the start of treatment, as well as defervescence,
successful treatment of any baseline fungal infection, absence of break-
through invasive fungal infection and no premature discontinuation due
to toxicity or lack of efficacy during treatment.
Statistical Analysis
Data management was performed by Quintiles N.V., Louvain-la-Neuve,
Belgium, and data analysis was carried out by ClinResearch, Cologne,
Germany using the SAS program version 6.12 (SAS Institute Inc., Cary,
NC, USA). Treatment equivalence was tested against the alternative that
ITRA is superior to AMB with respect to safety. Sample size calculations
were therefore based on the proportion of patients who permanently dis-
continued treatment because of any adverse event. In a recent study, this
proportion was 19% in the ITRA group compared to 38% in the AMB
group [10]. To detect this difference with 80% power at the two-sided 5%
significance level, 87 patients per treatment group were required. To ac-
count for a 20% dropout rate, 218 patients were planned to be enrolled.
Baseline demographic group comparison was calculated using Van El-
teren’s nonparametric test and Cochran-Mantel-Haenszel (CMH) test,
both controlled for stratification. The proportion of patients permanently
discontinuing treatment due to any adverse event was compared between
the groups using CMH and in subgroup analysis using χ2. The 95% confi-
dence interval (CI) was calculated for the difference in proportions be-
tween the treatments. Type and incidence of adverse events were tabulat-
ed per treatment group. The Kaplan-Meier estimate was employed for
the time until discontinuation of treatment and compared between the
groups using the stratified log rank test. For patients whose treatment did
not discontinue due to adverse events, time until discontinuation was cen-
sored at their last time point. Other safety parameters were analysed de-
scriptively, using the ‘last observation carried forward’ approach for miss-
ing data, if appropriate.
Efficacy parameters were descriptive. Time until defervescence was calcu-
lated using the Kaplan-Meier estimate. Differences in response and suc-
cess rates were calculated with 95% CI using the one-sided Fleiss test for
stratified equivalence for the total population and the one-sided Black-
welder test for subgroup analysis. The composite endpoint analysis was
performed with Fisher’s exact test (one-sided) and 95% CI limits; the
‘LOCF’ approach for missing data was not used.
Results
Due to slow recruitment, only 166 patients were enrolled into
the study. Of those, 162 patients (n = 81 for each treatment
group) were included in the safety analysis. As all these pa-
tients fulfilled the requirements for ITT analysis, they were all
included in the efficacy analysis. 31 patients switched treat-
ment (n = 10 ITRA, n = 21 AMB) and were evaluated for
safety and efficacy in the cross-over population.
Table 2 summarises the baseline demographic characteristics
of the study population. Both treatment groups compared
well. The age group 50–60 years was represented strongest in
both groups: 32.1% receiving ITRA, 27.2% receiving AMB.
The most common diagnosis was acute myeloid leukaemia
(52.2%). Antifungal prophylaxis before start of treatment was
given to 66.7% of the patients and consisted of nystatin (1.2%
for ITRA, 2.5% for AMB patients), ITRA (9.9% ITRA,
13.6% AMB), fluconazole (45.7% ITRA, 46.9% AMB) and
AMB (24.7% ITRA, 27.2% AMB). The mean daily dose of
AMB during treatment was 0.79 ± 0.22 mg/kg.
Safety
Study treatment was terminated prematurely for 53.7% of all
randomised patients. The main reasons were adverse events
(33.3%), subject asymptomatic/cured (6.2%) and insufficient
response (4.3%). 5 patients died during treatment (n = 3
ITRA, n = 2 AMB), 20 after completion of treatment (n = 10
in both groups) and 2 after completion of cross-over treatment
(n = 1 in each group). Fungal infection with Candida krusei
Table 1. Definition of evaluation criteria
Criterion Definition
Failure documented deep fungal infection or highly suggestive
CT scan, with progressive infiltrates
death due to fungal infection
persistent fever on day 28
deterioration of signs and symptoms potentially 
attributable to deep fungal infection (whether or not
fever disappeared on day 28)
empirical antifungal regimen changed by investigator
discontinuation of study medication due to poor tolerance
(also if treatment period is < 3 days)
Unevaluable treatment duration < 3 days, except when due to poor
tolerance
death not due to fungal infection
clinically and microbiologically documented bacterial or
viral infection alone responsible for the fever
Response not being classified into the failure or unevaluable 
category
patients who have received 10 days of study medication
and remained afebrile for at least 2 consecutive days 
(< 38 °C)
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caused one death in the ITRA group. Pneumonia and respira-
tory problems leading to death occurred in 3 of the ITRA pa-
tients and 8 of the AMB patients; 2 of the deaths in the AMB
group were caused by pulmonary aspergillosis and pneumonia
due to Pseudomonas, respectively. Multiple organ failure oc-
curred in 1 patient of each group.
Adverse events (independent of a causative relationship to
the study drug) during treatment were experienced by 79% in
the ITRA and 90.1% in the AMB group. Table 3 lists the most
frequent adverse events (incidence rate > 5%). Gastrointesti-
nal complaints and skin rash were more common for ITRA
patients, whereas patients receiving AMB experienced more
fever episodes, rigor, hypokalaemia and a rise in serum creati-
nine levels. Adverse events considered as ‘very likely’ related
to the study medication occurred less often in the ITRA
(7.4%) compared to the AMB group (51.9%). Severe adverse
events occurred in 17.3% of ITRA and 18.5% of AMB pa-
tients; the most frequent event originated in the respiratory
system (7.4% for each group). More AMB patients had to
permanently discontinue treatment due to an adverse event
(56.8%) compared to ITRA patients (22.2%; adjusted by stra-
ta). This difference was significant (–36 percentage points
(95% CI –51.1 to –20.8 percentage points); p < 0.0001). The
main reasons for withdrawal were increased serum creatinine
(1.2% for ITRA vs. 23.5% for AMB) and fever (1.2 vs.
11.1%). Significantly less renal toxicity occurred in ITRA
patients (3.7% compared to 40.7% for AMB patients; –39.1
percentage points (95% CI –52.6 to –25.6 percentage points);
p < 0.0001). Figure 1 shows the time to permanent discontinu-
ation of study medication due to any adverse event for the 
2 treatment groups. AMB patients left the study earlier than
patients in the ITRA group (9.3 ± 0.7 vs. 14.5 ± 0.6 days, Ka-
plan-Meier estimate; log-rank test χ2 = 24.36, p < 0.0001, ad-
justed across strata). A switchover from ITRA to AMB was
recorded for 12.3% of patients, from AMB to ITRA for
25.9% of patients.
Table 2. Baseline demographics of the study population (n = 162) and
stratification data
Itraconazole Amphotericin B 
(n = 81) (n = 81)
Gender (female), % 29.6 32.1a
Age, median (range), years 55.0 (18–73) 50.0b (18–76)
Underlying diagnosis, patients, %
Acute lymphatic leukaemia 7.4 14.8
Acute myeloid leukaemia 51.9 53.1




Treatment of haematological disease, patients, %
Total 70.4 71.6
Chemotherapy 29.6 28.4
Allogeneic SCT 14.8 16.0
Autologous SCT 2.5 2.5
PBSCT 23.5 23.5
Stratum, patients, n (%)
1: Allogeneic SCT 26 (32.1) 24 (29.6)
2: FUO with lung infiltrates 22 (27.2) 33 (40.7)
3: FUO 33 (40.7) 24 (29.6)
ap = 0.743.
bp = 0.11.
SCT = Stem cell transplant; PBSCT = peripheral blood stem cell 
transplant; FUO = fever of unknown origin.
Table 3. Most frequent adverse events, n (%) in the two treatment
groups; incidence rate > 5%
Adverse event Itraconazole Amphoteri- Total 
(n = 81) cin B (n = 81) (n = 162)
Increased serum creatinine 1 (1.2) 29 (35.8) 30 (48.6)
Hypokalaemia 5 (6.2) 16 (19.8) 21 (34.0)
Fever 7 (8.6) 13 (16) 20 (32.4)
Vomiting 12 (14.8) 7 (8.6) 19 (30.8)
Rigors 1 (1.2) 16 (19.8) 17 (27.6)
Diarrhoea 11 (13.6) 5 (6.2) 16 (25.9)
Bilirubinaemia 7 (8.6) 6 (7.4) 13 (21.1)
Nausea 8 (9.9) 4 (4.9) 12 (19.4)
Dyspnoea 4 (4.9) 8 (9.9) 12 (19.4)
Skin rash 8 (9.9) 4 (4.9) 12 (19.4)
Increased LDH 7 (8.6) 4 (4.9) 11 (17.8)
Agitation 5 (6.2) 5 (6.2) 10 (16.2)
Increased GGT 3 (3.7) 7 (8.6) 10 (16.2)
Increased BUN 2 (2.5) 7 (8.6) 9 (14.6)
LDH = Lactate dehydrogenase; GGT = gamma glutamyl transferase;
BUN = blood urea nitrogen.
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Fig. 1. Time to permanent discontinuation of itraconazole or amphoteri-
cin B treatment due to any adverse event for the safety population 
(n = 162). For patients whose treatment did not discontinue due to adver-
se events, time until discontinuation was censored at their last time point 
(ρ At least 1 discontinuation; ϕ censored only).




Overall, 18 fungal infections were observed in the ITT popula-
tion; 6 were baseline infections with positive cultures within 2
days of study enrolment. Only 1 patient (AMB) was treated
for > 3 days and failed; for the other infected patients, treat-
ment was discontinued earlier due to adverse events or lack of
efficacy. Breakthrough infections were based in the AMB
group on cultures from sterile sites in 3 patients (1 Aspergillus,
2 C. spp.), and on the combination of bronchoalveolar lavage
(BAL) and radiological findings in 2 patients (C. albicans and
Aspergillus plus C. spp.). In the ITRA group, breakthrough in-
fections were based on cultures from sterile sites in 3 patients
(1 Aspergillus, 1 C. krusei, 1 C. spp.), and on the combination
of BAL and radiological findings in 2 patients (1 Aspergillus, 1
mixed infection). In 2 patients (1 AMB, 1 ITRA), the diagnosis
was based on repeated CT scans only. Given the more strin-
gent EORTC criteria, the latter patients would not have ful-
filled the diagnostic criteria of proven or probable infection.
Due to the high rate of early cross-over or switch to other
available antimycotics, the first positive culture was observed
only after termination of the initial treatment in 7/12 cases (5
AMB, 2 ITRA). The results are summarized in table 4.
Time to treatment response was higher for ITRA patients
(17.2 ± 0.9 days) than for AMB patients (13.6 ± 1.3 days, mean
Kaplan-Meier). The number of febrile days was also slightly
higher in the itraconazole group: 5.1 ± 3.8 days compared to
4.1 ± 4.0 days. Defervescence (remaining afebrile for at least 2
consecutive days) was achieved in 69.1% of ITRA patients
compared to 60.5% of AMB patients. Median time to defer-
vescence was 4 days for ITRA vs. 3 days for AMB.
Both the response rate and the success rate were in favour of
ITRA treatment. The response rate was 61.7% for ITRA
compared to 42% for AMB, and the success rate was 70.4%
vs. 49.3%. Both differences between the treatment groups
were significant (p < 0.0001). Failure of treatment occurred
more frequently in AMB (43.2%) than in ITRA patients
(25.9%).
For the ITT analysis, 50 patients for stratum 1, 55 for stratum 2
and 57 for stratum 3 were available (table 2). A subgroup
analysis of the response and success rates in the 3 strata yield-
ed similar results. The response rate was 61.5% ITRA vs.
33.3% AMB (stratum 1; p = 0.001), 54.5 vs. 45.5% (stratum 2;
p = 0.038) and 66.7 vs. 45.8% (stratum 3, p = 0.003). For the
success rate, the following proportions were found: stratum 1
(69.6 vs. 40%, p = 0.0015), stratum 2 (66.7 vs. 55.6%, p = 0.04)
and stratum 3 (73.3 vs. 50%, p = 0.002). All other subgroup
analyses revealed safety and efficacy profiles similar to the
main analysis.
5 ITT patients could not be included in the composite end-
point analysis, therefore 157 patients were evaluated. The
analysis showed an overall response to ITRA for 43 patients
(55.1%) and to AMB for 21 patients (26.6%). The difference
of 28.55 percentage points (95% CI 13.8–43.3 percentage
points) was significant (p = 0.0002).
Discussion
ITRA was tolerated significantly better as empirical antifun-
gal therapy in this high-risk patient population than AMB. Al-
though overall mortality was similar for the 2 treatment
groups, adverse events were much less frequent in ITRA pa-
tients, and only half as many ITRA as AMB patients had to
switch treatment. The incidence of infusion-related events was
higher in AMB patients. Nearly 20% of these patients experi-
enced rigors. Hypokalaemia and nephrotoxicity were also
much less frequent in ITRA compared to AMB patients. Sev-
eral studies have reported an association of conventional
AMB with these side effects. The proportion of patients expe-
riencing hypokalaemia ranged from 11.6 to 48% [5, 10, 12–14]
and of those developing nephrotoxicity from 11 to 51.5% [3–5,
10, 12–14] in these studies. The development of metabolic tox-
icities might require discontinuation of medication. Indeed,
the main reason for AMB patients to withdraw from the pre-
sent study was increased serum creatinine (23.5% compared
to 1.2% for ITRA patients), and permanent discontinuation
due to any adverse event was significantly higher than in
ITRA patients. AMB patients also discontinued study med-
Itracona- Amphoteri- P value
zole cin B
Discontinued treatment due to any adverse event, % 22.2 56.8 < 0.0001
Average treatment period, days 14.5 9.3 < 0.0001
Response rate, % 61.7 42 < 0.0001
Success rate, % 70.4 49.3 < 0.0001
Composite endpoint (according to Walsh [5]), % 55.1 26.6 0.0002
Fungal infections
Baseline 4 2 n.s.
Breakthrougha 6 6 n.s.
a1 in each group based on CT scans only.
n.s. = Not significant.
Table 4. Summary of treatment results
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ication earlier. The withdrawal rate for ITRA patients is simi-
lar to that found by Boogaerts et al. [10]; the rate for AMB
patients was, however, much higher in the present study (38
vs. 56.8%). The assessment of the withdrawal rates according
to strata yielded similar results: rates of 62.5, 48.5 and 62.5%
were found for the 3 strata, respectively. Drug-related adverse
events also occurred less when administering ITRA (the pro-
portions were similar to Boogaerts et al [10]); severe adverse
events, however, occurred twice as often in their amphotericin
group than in our study. The most favourable safety aspect of
ITRA was the near absence of renal toxicity. Only 3.7 vs.
40.7% of AMB patients experienced renal toxicity. This trans-
lates into an advantage of treatment with ITRA in patients
with existing or developing renal insufficiency as well as in pa-
tients requiring concomitant treatment with other nephrotoxic
agents such as aminoglycosides or cyclosporin. A reduced risk
of renal toxicity was established in a recent systematic review
for lipid-based amphotericin formulations but efficacy proved
to be similar to conventional AMB [6].
The incidence of systemic infection was low and occurred at a
similar rate in both treatment groups. A similar proportion of
patients achieved defervescence. The higher efficacy of ITRA
at similar time to defervescence can be based on the rate of
complications under AMB treatment.
ITRA proved more efficacious than AMB in this study. Both
the response and success rates were significantly higher, and
treatment failure was markedly reduced when ITRA was ad-
ministered. Overall response according to composite endpoint
analysis was seen in twice as many ITRA patients (43 vs. 21).
The overall response to ITRA of 55.1% confirms the data of
Boogaerts et al. (53% [10]), but the outcome for AMB was
much lower in the present study (26.6 vs. 46%). Treatment
failure was less frequent in our study. The subgroup analysis
showed no difference in treatment response or tolerability of
the study medication between the 3 strata. ITRA compared
favourably to AMB in all 3 patient groups. Rates of fungal in-
fections were not a primary endpoint of the study but were
comparable in both groups. Due to the small number of pa-
tients finishing the initial therapy, successful therapy of base-
line or emerging infections cannot be evaluated. One has to
keep in mind that the superior efficacy of ITRA is based ex-
clusively on superior tolerability in this study.
Our results are limited by the open-label design of the study.
The fact that investigators were not blinded to study medica-
tion might have biased the reporting of drug-related adverse
events and treatment response. This makes it impossible to
compare the composite endpoint percentages across studies. It
should also be noted that the study was powered for safety
and not for efficacy.
Newer and more costly drugs continue to be evaluated for
proven infection [15] and in the empirical setting [16]. In the
absence of comparative studies, only indirect conclusions of
comparative merits both in antifungal efficacy, side effects and
cost efficiency can be derived. ITRA shares the obvious ad-
vantage of oral availability with voriconazole but does not
show the side effect of altered vision. Despite the compelling
data in proven infection [15], data in support of voriconazole
in the empirical setting were less favourable [7]. On this basis,
voriconazole has not yet been approved for empirical therapy
in several countries. Caspofungin is another tempting alterna-
tive [16], however, in comparison to ITRA the considerably
higher price limits its administration to more highly selected
patients.
In conclusion, our results have confirmed a role of ITRA as a
safe and efficacious alternative to conventional AMB as em-
pirical antifungal therapy for neutropenic fever in patients
with haematological malignancies.
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